Welcome back to Research Roundup! Today you can find recent studies on musculocontractural Ehlers-Danlos syndrome (mcEDS), vascular Ehlers-Danlos syndrome (vEDS), hypermobile Ehlers-Danlos syndrome (hEDS), and hypermobility spectrum disorders (HSD).
These studies explored emergency care after minor trauma in mcEDS, bone structure changes linked to dermatan sulfate deficiency, experiences with celiprolol treatment in vEDS, gut-brain interaction disorders and altered food intake behaviors, and reflux and swallowing symptoms in hEDS and HSD.
Recurrent massive hematoma after trivial trauma in Ehlers–Danlos syndrome: a case report highlighting diagnostic urgency and surgical challenges
A case report described a 10-year-old with musculocontractural Ehlers-Danlos syndrome (mcEDS) who developed a severe hematoma after a minor fall. Treatment included staged wound care, tissue removal, and skin grafting to prevent further tissue damage and support recovery.
These findings highlight how tissue fragility in mcEDS may lead to serious complications after minor injuries.
Authors: Ahmed M, Bhat H, Nissar Y, Al-Mohannadi F, Babiker H
DOI: 10.1093/jscr/rjag367
Comprehensive analysis of the skeletal phenotype in Chst14-/-mice: implications for dermatan sulfate in bone structure and strength
A mouse study explored how dermatan sulfate deficiency affects bone structure in mcEDS. Researchers found progressive spinal and hip changes, lower bone strength, and reduced bone mass in affected mice.
These findings may improve understanding of how skeletal changes develop in mcEDS. As this study was conducted in mice, the results may not directly apply to humans.
Authors: Takahashi Y, Yoshizawa T, Mizumoto S, Ono F, Uehara M, Watanabe T, Shimada S, Nitahara-Kasahara Y, Yamada S, Takahashi J, Okada T, Kosho T
Clinical Outcomes and Patient Experiences With Celiprolol Therapy in Vascular Ehlers-Danlos Syndrome: The First Non‐European Cohort
Researchers found that celiprolol treatment may reduce fatal vascular events in people with vascular Ehlers-Danlos syndrome (vEDS), although nonfatal complications still occurred.
Interviews with 11 of the 26 participants suggested it also provided emotional reassurance and supported a more proactive approach to managing the condition.
Authors: Furuhata‐Yoshimura M, Yamaguchi T, Kosho T
DOI: 10.1002/ajmg.a.70178
A Clinical Practice Update for the Management of Patients With Disorders of Gut-Brain Interaction and Altered Food Intake Behavior
Researchers developed guidance for Disorders of Gut-Brain Interaction linked to Altered Food Intake Behaviors (DGBI-AFIB). The guidelines emphasized multidisciplinary care and distinguishing these symptoms from eating disorders.
Findings also suggested an increased association between DGBI-AFIB and:
- hypermobility spectrum disorders (HSDs)
- postural orthostatic tachycardia syndrome (POTS)
- mast cell activation syndrome (MCAS)
- vascular compression syndromes
Authors: Shah A, Talley N, Knowles S, Duncanson K, Koloski N, Connor J, Day A, Almehdawy B, Basnayake C, Burgell R, Carey S, Cock C, Daker C, Kaushik V, Kent D, Kellar T, Lane K, Martin N, Malcolm A, Murphy K, Sharp G, Tuck C, Jones M, Thapar N, Holtmann G
DOI: 10.1111/nmo.70337
Esophageal Dysmotility and Gastroesophageal Reflux Disease Risk in Hypermobile Ehlers-Danlos Syndrome
A study found that hypermobile Ehlers-Danlos syndrome (hEDS) and HSD were not associated with esophageal dysmotility or gastroesophageal reflux disease (GERD). Functional heartburn was the most common diagnosis in people with hEDS or HSD, affecting 63% of participants.
These findings contribute to growing research into reflux and swallowing symptoms in hEDS and HSD.
Authors: Butt M, Dervin H, Hoshino S, Yazaki E, Gerard P, Sweis R, Sifrim D, Aziz Q, Zárate-López N, Fikree A
DOI: 10.1016/j.cgh.2026.04.019
